Advertisement

Search Results

Advertisement



Your search for ,twO matches 11990 pages

Showing 51 - 100


gynecologic cancers

Adjuvant Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer

In a study reported in JAMA Oncology, Agusti et al found that the addition of chemotherapy to adjuvant radiotherapy was not associated with improved overall survival in patients with intermediate-risk cervical cancer. Study Details The study involved National Cancer Database data on patients with a ...

integrative oncology

Building and Sharing Dietary Evidence in Cancer Care

Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested in exploring different dietary interventions throughout the cancer continuum. However, concrete...

neuroendocrine tumors

FDA Approves Cabozantinib for pNET and epNET

Today, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors...

solid tumors
hematologic malignancies
issues in oncology

Are New-Onset Type 2 Diabetes and Obesity-Related Cancers Linked?

A new diagnosis of type 2 diabetes may be linked to a subsequent increased risk of developing some obesity-related cancers, according to new findings presented at the European Congress on Obesity (ECO) 2025. Background Previous research has uncovered associations between type 2 diabetes and a...

gynecologic cancers

Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?

Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced...

solid tumors
hematologic malignancies
issues in oncology

Sex Differences in Waist Circumference vs BMI as Risk Factors for Obesity-Related Cancers

Waist circumference may be a more effective risk marker for the development of obesity-related cancers than body mass index (BMI) in male but not female patients, according to new findings presented at the European Congress on Obesity (ECO) 2025. Background Body size and excess...

HER2-Selective TKI in Advanced Solid Tumors with HER2 Alterations

In a phase Ia/Ib study (Beamion LUNG-1) reported in the Journal of Clinical Oncology, Heymach et al evaluated the safety profile and activity of zongertinib in patients with HER2-altered solid tumors. Zongertinib is a novel HER2-selective tyrosine kinase inhibitor (TKI) that spares EGFR, thereby...

prostate cancer

Microultrasound- vs MRI-Guided Biopsy for Prostate Cancer Diagnosis

Biopsies guided by high-resolution ultrasound may be as effective as those using magnetic resonance imaging (MRI) in diagnosing prostate cancer, an international clinical trial has shown. The technology, called micro-ultrasound, is cheaper and easier to use than MRI. It could significantly speed up ...

bladder cancer

TB Vaccination Could Enhance BCG Response in Patients With Non–Muscle-Invasive Bladder Cancer, Study Finds

Two doses of a simple tuberculosis (TB) vaccination after surgery helps the immune system fight cancer cells and may improve patient outcomes among those with non–muscle-invasive bladder cancer, according to a pilot study of 40 patients. Initial results from the RUTIVAC-1 Trial were presented by...

breast cancer

Conundrums in Treating HER2-Positive Early Breast Cancer

Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios. Dr. Hurvitz is...

issues in oncology

New Reports Assess Oncology Workforce Well-Being, Propose Solutions to Address Burnout

Physician burnout has increased significantly in the past decade, and organizational strategies are vital to improve physician well-being, according to new research from ASCO. This compilation includes reports on the state of professional well-being among oncologists in 2023, burnout trends among...

leukemia
lymphoma

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

“Care more particularly for the individual patient than for the special features of the disease.” —Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...

lymphoma

Benefit Suggested for Early Treatment of Advanced-Stage, Very Low–Tumor Burden Follicular Lymphoma

In the phase III JCOG1411/FLORA trial of patients with untreated advanced-stage, very low–tumor burden follicular lymphoma, rituximab induction delayed disease progression to high–tumor burden follicular lymphoma and delayed the initiation of cytotoxic chemotherapy, according to Japanese...

lymphoma

inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma

The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...

lymphoma

Recent FDA Approvals in Lymphoma and in Rarer Tumors

The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising ...

solid tumors

Intraperitoneal Paclitaxel Combination Regimen Improves Overall Survival in Advanced Gastric Cancer

Adding intraperitoneal (IP) paclitaxel to standard intravenous (IV) paclitaxel plus S-1 (oral fluoropyrimidine derivative) significantly extended overall survival for patients with gastric cancer peritoneal metastases, according to data presented at the 2025 ASCO Gastrointestinal Cancers...

lung cancer

Advanced PD-L1–Positive NSCLC: Ivonescimab vs Pembrolizumab

In an interim analysis of a Chinese phase III trial (HARMONi) reported in The Lancet, Xiong et al found that ivonescimab—a bispecific antibody against PD-1 and VEGF—significantly improved progression-free survival vs pembrolizumab in the first-line setting for patients with advanced PD-L1–positive...

breast cancer
supportive care

Techniques for Preventing Taxane-Induced Neuropathy in Breast Cancer

In a German single-center trial (POLAR) reported in JAMA Oncology, Michel et al found that hand cooling and hand compression were associated with a reduced risk of taxane-induced neuropathy in women with primary breast cancer. Study Details In the trial, 101 patients enrolled at the National Center ...

skin cancer

Definitive Radiation Therapy Effectively Treats Locally Advanced BCC

Definitive radiation therapy offers a high degree of locoregional control in large, locally advanced basal cell carcinomas (BCC), according to results from a recent multi-institutional research study published by Su et al in the International Journal of Radiation Oncology · Biology · Physics. One...

breast cancer

Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?

With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which patients, however, might safely forgo the current recommendations and be safely followed with active...

colorectal cancer
hepatobiliary cancer
gastrointestinal cancer

In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers

The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators ...

issues in oncology

Do Congenital Heart Defects Affect Cancer Risk in Newborns and Their Mothers?

Newborns with congenital heart defects may have a higher risk of developing childhood cancer compared to children born without a heart abnormality. Further, congenital heart defects in newborns may also signal an elevated cancer risk for their mothers. These findings were published recently by Huh...

gynecologic cancers
issues in oncology
immunotherapy

Advances in Endometrial Cancer Detection, Treatment

Two novel studies may provide insights into advancements in the detection and treatment of endometrial cancer, according to new findings presented by Moore et al and Nolin et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer.  Together, the two studies...

lymphoma

Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD

Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society ...

head and neck cancer
immunotherapy

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug, according to a recent study published by Li et al in Cancer Cell. Background Head and neck squamous cell carcinomas occur in the...

prostate cancer

Addition of Pembrolizumab to Chemotherapy for Previously Treated Metastatic Castration-Resistant Prostate Cancer

As reported in the Journal of Clinical Oncology by Petrylak et al, the phase III KEYNOTE-921 trial showed no benefit in outcomes with the addition of pembrolizumab to docetaxel in patients with previously treated metastatic castration-resistant prostate cancer. Study Details In the global...

genomics/genetics
solid tumors
issues in oncology

Two Initiatives Could Help Increase Oncogene Testing in Primary Care Settings

Investigators may have identified new strategies for use in the primary care setting to improve the detection of cancer-susceptibility genes, according to a recent study published by Swisher et al in JAMA Network Open. Background Up to 10% of cancers—including breast cancer, ovarian cancer,...

issues in oncology

Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop

Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...

head and neck cancer
issues in oncology
immunotherapy

Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer

Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma, according to a recent study published by Rosenberg et al in...

integrative oncology

Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment

Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...

breast cancer

Discussing Breast Density With Patients Following the FDA Mammography Quality Standards Act Mandate

In JAMA, Lee et al provided a concise, evidence-based summary to help clinicians discuss information regarding breast density and implement shared decision-making with patients following the U.S. Food and Drug Administration (FDA) Mammography Quality Standards Act mandate. Since September 2024,...

breast cancer
issues in oncology

Breast Cancer Mortality Rates May Have Stopped Declining

Breast cancer mortality rates may have stopped declining in women older than 74 years and younger than 40 years, according to a recent study published by Monticciolo and Hendrick in the Journal of Breast Imaging. Background Breast cancer is the second leading cause of cancer-related mortality among ...

issues in oncology
global cancer care
health-care policy

How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World

Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...

solid tumors
immunotherapy

Combination of Immunotherapies for Advanced HPV-Associated Cancers

In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...

hematologic malignancies
multiple myeloma

MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma

In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...

lung cancer
supportive care

Prophylactic Strategy for Preventing Infusion-Related Reactions With IV Amivantamab in EGFR-Mutated NSCLC

Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...

issues in oncology

Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?

It’s a fast-paced world, no two ways about it. People move on from one event to another. We have to move on either for our own sake or the sake of someone near and dear. In the medical field, patients come and go, surgeries are performed, treatments are given, and everybody moves on. Being kind to...

breast cancer
issues in oncology

Breast-Conserving Surgery Linked to Improved Sexual Well-Being Compared With Postmastectomy Breast Reconstruction

Breast-conserving therapy may be associated with improved sexual well-being compared with mastectomy followed by breast reconstruction in patients with breast cancer, according to a recent study published by Stern et al in Plastic and Reconstructive Surgery. Background Many patients with breast...

prostate cancer

Overall Survival and HRQOL with Addition of  [177Lu]Lu-PSMA-617 to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

In an analysis of an Australian phase II trial (ENZA-p) reported in The Lancet Oncology, Emmett et al reported that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved overall survival and several aspects of health-related quality of life (HRQOL) in the first-line...

breast cancer

Top Picks From SABCS 2024

Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...

prostate cancer
genomics/genetics

BRCA1 Gene Mutations May Not Be Key to Prostate Cancer

Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...

colorectal cancer
survivorship
issues in oncology

Physical Activity May Help Colorectal Cancer Survivors Live as Long as Those in General Population

Physical activity may help colorectal cancer survivors achieve long-term survival rates comparable to those of individuals in the general population, according to a recent study published by Brown et al in Cancer. Background Patients with colorectal cancer often face higher rates of premature...

skin cancer

Immunotherapy for Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy

In a single-center retrospective study reported in JAMA Oncology, Lochrin et al identified activity of ipilimumab/nivolumab in melanoma brain metastases after progression on anti–PD-1 treatment. Study Details The study involved 28 patients with prior PD-1 inhibitor treatment who developed...

The Death of Alexei Navalny and the Discovery of Cancer Chemotherapy

Remembering  Alexi Anatolyevich Navalny: The Russian opposition leader, lawyer, anticorruption activist, and political prisoner, Alexi Navalny died in the Arctic Wolf prison in Siberia approximately 1 year ago on February 16, 2024.  He was designated a Prisoner of Conscience by Amnesty...

hematologic malignancies
multiple myeloma

Effect of High-Risk Cytogenetic Abnormalities in Multiple Myeloma

In a retrospective study reported in the Journal of Clinical Oncology, Kaiser et al found that the presence of two or more high-risk cytogenetic abnormalities was associated with poorer outcomes in patients with newly diagnosed multiple myeloma (MM) and relapsed or refractory MM. Study Details The...

breast cancer
supportive care

Cryotherapy With Taxane Infusion: Strategy for Preventing Peripheral Neuropathy in Breast Cancer

In a meta-analysis reported in the journal Breast Cancer Research and Treatment, Kumar et al found that the use of cryotherapy decreased the incidence of moderate or worse peripheral neuropathy by more than 50% in patients with breast cancer who received paclitaxel or nab-paclitaxel. Cryotherapy...

multiple myeloma
genomics/genetics
issues in oncology

Genetic Testing May Identify High-Risk Cytogenetic Abnormalities in Patients With Multiple Myeloma

Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....

lymphoma
immunotherapy

Novel CD19-1XX CAR With Calibrated Signaling in LBCL

In a single-institution phase I study reported in the Journal of Clinical Oncology, Jae H. Park, MD, and colleagues found that first-in-human use of a CD19-1XX chimeric antigen receptor (CAR) T-cell therapy with calibrated signaling showed high activity in patients with relapsed or refractory large ...

lymphoma
leukemia

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

“Care more particularly for the individual patient than for the special features of the disease.”—Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...

bladder cancer

Combination Immunotherapy Plus Radiotherapy in Muscle-Invasive Bladder Cancer

Studies show that although radical cystectomy has long been recognized as the standard-of-care for localized muscle-invasive bladder cancer (MIBC), the surgery carries significant morbidity and the risk of subsequent loss of quality of life for patients. Preclinical studies have suggested that a...

Advertisement

Advertisement




Advertisement